RxDoctor Payments Data

Jason Fagan, PA

Physician Assistant · Davenport, FLNPI 1538418934

Payments from drug & device makers

$1,242in general payments, 2019–2025

Across 50 payments — averaging $24.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Averitas Pharma Inc.$259
  • Scilex Pharmaceuticals Inc.$128
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$125
  • Protega Pharmaceutials Inc$123
  • Nevro Corp.$122
  • Abbott$103
  • plus $382 from 13 others

What the payments were for

  • Food & beverage$1,242100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,242 in reported general payments places this provider in the 65th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$156,840
Medicare patients
159
Services billed
1,935

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide14$31,213
UbrelvyUbrogepant18$21,819
Lidocaine137$18,780
ZtlidoLidocaine12$7,496
Diclofenac Potassium18$7,144
Diclofenac Sodium172$5,954
Gabapentin309$4,111
Tizanidine Hcl239$2,184
Celecoxib38$1,919
Cyclobenzaprine Hcl148$1,623
Methocarbamol114$1,603
Naloxone Hcl16$939
Baclofen128$841
Meloxicam234$506
Duloxetine Hcl16$291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$125$31,21314 claims
AbbVieUbrelvy$51$21,81918 claims
Scilex Pharmaceuticals Inc.Ztlido$128$7,49612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Davenport

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →